Viatris Reaffirms FY21 Revenue Outlook, Declares Dividend - Quick Facts

While reporting financial results for the first quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2021.

For fiscal 2021, the company continues to project total revenue between $17.2 billion and $17.8 billion. On average, 13 analysts polled by Thomson Reuters expect the company to report revenues of $17.50 billion.

The company also said its Board of Directors declared a quarterly dividend of $0.11 for each issued and outstanding share of the company's common stock, payable on June 26, 2021 to stockholders of record at the close of business on May 24, 2021.

"We see underlying strength in our business and we are reaffirming guidance for 2021, which incorporates known and potential headwinds and tailwinds for the remainder of the year. At the conclusion of the second quarter, we will be reassessing our guidance for the full year," said Michael Goettler, CEO.

The company noted that it is encouraged that their new product launches delivered revenue of $163 million for the quarter and remain on track to meet the $690 million target in new product launch revenue for the year. It is also on track to realize approximately $500 million of cost synergies this year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT